An international clinical trial is underway to evaluate on a large scale the effects of the first specific treatment for Polycystic Ovary Syndrome, a condition that affects between 5 and 10% of women of reproductive age. This syndrome can cause increased body hair and acne, irregular menstrual periods, and fertility problems.
PCOS is the most common endocrine disorder in women of reproductive age, but, at the same time, it is one of the most unknown pathologies among the general population. It can also lead to the development of other diseases such as type 2 diabetes, cancer before menopause and anxiety or depression, which has an impact on the quality of life of these women.
At ASPHALION, we are proud regulatory partners of this EU-funded HORIZON project. We are committed to improving women’s health!
The clinical trial is aimed for the first time at treating the cause of the condition, rather than simply alleviating its symptoms, as is currently the case. Women diagnosed with Polycystic Ovary Syndrome between 12 and 24 years old can participate in this clinical trial if they have irregular menstruation, excess hair growth and/or persistent and severe acne. The recruitment period spans until April 2024.
People interested in taking part in the clinical trial can contact the research staff via the website: https://spiomet4health.eu/the-clinical-trial/#en or by sending an e-mail to: [email protected].
For further information, you can contact us at: [email protected]
